Imunon (CLSN) Stock Analysis

What Imunon does

Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.

Key metrics

ETFs linked to CLSN

Broad-market and Healthcare sector ETFs an investor holding Imunon is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CLSN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Imunon?

Imunon trades under the ticker CLSN on NASDAQ.

Which exchange is CLSN listed on?

CLSN is listed on NASDAQ.

What sector does Imunon operate in?

Imunon is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CLSN in a portfolio?

PortView shows CLSN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.